TransMedics Group (TMDX) Tops Q4 EPS by $2.23, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $2.62, $2.23 better than the analyst estimate of $0.39. Revenue for the quarter came in at $160.8 million versus the consensus estimate of $155.98 million.

GUIDANCE:

TransMedics Group sees FY2026 revenue of $727-757 million, versus the consensus of $725 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tapestry Inc. (TPR) PT Raised to $185 at Bernstein SocGen Group
• StablecoinX reports Q2 2026 results with $34.2M net loss